4G4G genotype of PAI-1 gene promoter polymorphism is not associated with myocardial infarction in caucasians with type-2 diabetes [2]

Cardiology

Volumn 100, Issue 3, 2003, Pages 157-158

  Petroviĉ, Danijel ^a,c   Globoĉnik Petroviĉ, Mojca ^b   Peterlin, Borut ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CAUCASIAN; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEART INFARCTION; HUMAN; INCIDENCE; LETTER; MALE; MEDICAL ETHICS; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROMOTER REGION; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; THROMBOSIS; WORLD HEALTH ORGANIZATION;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROBABILITY; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0344826486     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073935     Document Type: Letter

References (8)

1. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: Risk for recurrent myocardial infarction. Lancet 1987;2:3-9.
2. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - Relationship with plasma insulin. Thromb Haemost 1989;61: 370-373.
3. Mansfield MW, Stickland MH, Grant PJ: Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995:74:842-847.
4. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ: Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001; 104:3063-3068.
5. Gardemann A; Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W: The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999;82:1121-1126.
6. Ridker PM, Hennekens CH, Lindpaintner K, Stempfer MJ, Miletich JP: Arterial and venous thrombosis is not associated with the 4G5G polymorphism in the promoter region of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
8. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627-631.